ORTHOCELL LIMITED (OCC)
Share Price Analysis and Chart

19/03/2026

1

Initiation of coverage with Speculative Buy

$1.15

58.62%

Bell Potter initiates coverage on regenerative medicine company Orthocell with a $1.15 target and Speculative Buy rating.

Having achieved FDA approval last April for nerve repair product Remplir, the early US commercial rollout is targeting an underpenetrated market, the broker explains.

Remplir’s differentiated design and positioning support adoption, the analysts suggest, with growth driven by procedural demand rather than displacement of existing products.

Bell Potter believes the company is well funded with $49.4m cash and expects rising revenue to improve operating leverage, despite near-term elevated cash burn.

Execution across distribution, surgeon uptake and repeat procedures are seen as key near-term drivers, with broader expansion offering upside.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.10 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.10 cents.

18/12/2025

1

Initiation of coverage with Speculative Buy

$1.33

83.45%

Canaccord Genuity has initiated coverage of Orthocell with a Speculative Buy rating and target price of $1.33.

The company is a regenerative medicine company focused on collagen-based devices for peripheral nerve repair. The lead product, Remplir, a collagen nerve wrap to aid regeneration and reduce scarring, has secured major global approvals, including FDA 510(k) in April 2025, setting up a multi-year growth runway.

The company is beginning its US rollout using a capital-light distributor model, guided by an in-house commercial team experienced in nerve repair.

The broker reckons the company is moving into a 12–24 month period where rising VAC uptake, greater surgeon familiarity, and strengthening clinical data could meaningfully de-risk its revenue outlook.

FORECAST
Canaccord Genuity forecasts a full year FY26 EPS of minus -3.00 cents.
Canaccord Genuity forecasts a full year FY27 EPS of minus -1.00 cents.